Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells

Gastric Cancer

Volumn 19, Issue 1, 2016, Pages 53-62

  Grygielewicz, Paulina ^a,b   Dymek, Barbara ^a   Bujak, Anna ^a,b   Gunerka, Pawel ^a,c   Stanczak, Aleksandra ^a   Lamparska Przybysz, Monika ^a   Wieczorek, Maciej ^a   Dzwonek, Karolina ^a,d   Zdzalik, Daria ^a  

^a Celon Pharma Ltd   (Poland)

^b POSTGRADUATE SCHOOL OF MOLECULAR MEDICINE   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

AZD4547; BGJ398; Drug resistance; Epithelial mesenchymal transition; Fibroblast growth factor receptor; Fibroblast growth factor receptor inhibitor

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; AZD 4547; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR RECEPTOR; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3; INFIGRATINIB; LUMINESPIB; MITOGEN ACTIVATED PROTEIN KINASE; MUBRITINIB; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE INHIBITOR; SB 525334; SCATTER FACTOR RECEPTOR; SMAD2 PROTEIN; SMAD3 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; 3-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-1-(6-(4-(4-ETHYLPIPERAZIN-1-YL)-PHENYLAMINO)PYRIMIDIN-4-YL)-1-METHYLUREA; 5-(2,4-DIHYDROXY-5-ISOPROPYLPHENYL)-4-(4-MORPHOLIN-4-YLMETHYLPHENYL)ISOXAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CARBANILAMIDE DERIVATIVE; FGFR2 PROTEIN, HUMAN; ISOXAZOLE DERIVATIVE; OXAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; RESORCINOL DERIVATIVE; TAK-165; TRIAZOLE DERIVATIVE;

ARTICLE; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SNU 16 CELL LINE; UPREGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; ISOXAZOLES; MOLECULAR TARGETED THERAPY; OXAZOLES; PHENYLUREA COMPOUNDS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, FIBROBLAST GROWTH FACTOR; RESORCINOLS; STOMACH NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1; TRIAZOLES;

EID: 84951566838     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-014-0444-1     Document Type: Article

References (47)

1. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16(2):139–49.
2. Kunii K, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008;68(7):2340–8.
3. Gru AA, Allred DC. FGFR1 amplification and the progression of non-invasive to invasive breast cancer. Breast Cancer Res. 2012;14(6):116.
4. Billerey C, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158(6):1955–9.
5. Pollock PM, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 2007;26(50):7158–62.
6. Liao RG, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013;73(16):5195–205.
7. Chesi M, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16(3):260–4.
8. Singh D, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337(6099):1231–5.
9. Dieci MV, et al. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013;3(3):264–79.
10. Mohammadi M, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998;17(20):5896–904.
11. Gavine PR, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72(8):2045–56.
12. Guagnano V, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011;54(20):7066–83.
13. Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
14. Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol. 2010;17(1):14–7.
15. Zhao G, et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther. 2011;10(11):2200–10.
16. Guagnano V, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118–33.
17. Chell V, et al. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene. 2013;32(25):3059–70.
18. Byron SA, et al. The N550 K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia. 2013;15(8):975–88.
19. Harbinski F, et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov. 2012;2(10):948–59.
20. Herrera-Abreu MT, et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 2013;3(9):1058–71.
21. Bar-Am I, et al. Detection of amplified DNA sequences in human tumor cell lines by fluorescence in situ hybridization. Genes Chromosomes Cancer. 1992;4(4):314–20.
22. Xie L, et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res. 2013;19(9):2572–83.
23. Ku JL, Park JG. Biology of SNU cell lines. Cancer Res Treat. 2005;37(1):1–19.
24. Rho JK, et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer. 2009;63(2):219–26.
25. Brunen D, et al. TGF-β: an emerging player in drug resistance. Cell Cycle. 2013;12(18):2960–8.
26. Yauch RL, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res. 2005;11(24 Pt 1):8686–98.
27. Thomson S, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005;65(20):9455–62.
28. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009;1796(2):75–90.
29. Chaw SY, et al. Epithelial to mesenchymal transition (EMT) biomarkers – E-cadherin, beta-catenin, APC and vimentin – in oral squamous cell carcinogenesis and transformation. Oral Oncol. 2012;48(10):997–1006.
30. Kato N, et al. β-Catenin activation and epithelial-mesenchymal transition in the pathogenesis of pterygium. Invest Ophthalmol Vis Sci. 2007;48(4):1511–7.
31. Oft M, et al. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 1996;10(19):2462–77.
32. Gal A, et al. Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene. 2008;27(9):1218–30.
33. Kim YJ, et al. Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine. Anticancer Res. 2012;32(3):799–806.
34. Kim HR, et al. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol Oncol. 2013;7(6):1093–102.
35. van Malenstein H, et al. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 2013;329(1):74–83.
36. Wang J et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2014. doi:10.1038/onc.2014.161.
37. Hanze J, et al. Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells. BMC Cancer. 2013;13:589.
38. Nguyen PT, et al. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1. Br J Cancer. 2013;109(8):2248–58.
39. Warzecha CC, et al. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell. 2009;33(5):591–601.
40. Shirakihara T, et al. TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J. 2011;30(4):783–95.
41. De Medina SG, et al. Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas. Oncogene. 1999;18(41):5722–6.
42. Bai A, et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 2010;70(19):7630–9.
43. Huang S, et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell. 2012;151(5):937–50.
44. Yao Z, et al. TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A. 2010;107(35):15535–40.
45. Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012;11(10):790–811.
46. Morrison CD, Parvani JG, Schiemann WP. The relevance of the TGF-β paradox to EMT-MET programs. Cancer Lett. 2013;341(1):30–40.
47. Suda K, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol. 2011;6(7):1152–61.